Multiplexed Engineering of Salmonella Typhimurium for Targeted Cancer Therapies
ACS Synthetic Biology · 2026
DOI: 10.1021/acssynbio.6c00119 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Synthetic Biology, 2026. Verfasst von Xiaoli Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Synthetic Biology and Biomanufacturing, Key Laboratory of Systems Bioengineering (Ministry of Education), State Key Laboratory of Synthetic…. Hauptthemen laut MEDLINE: Salmonella typhimurium, Neoplasms, Genetic Engineering. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 198 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Synthetic biology has driven growing interest in engineered bacteria for cancer therapy. Salmonella Typhimurium stands out as one of the most promising live biotherapeutic products (LBPs) because of its innate tumor-targeting and colonizing abilities. However, the pathogenicity and inconsistent performance of wild-type S. Typhimurium have hindered further clinical translation. Recent advances in programmable and modular genetic redesign now enable precise reprogramming of bacterial functions, facilitating the creation of customized LBPs with enhanced safety and efficacy. In this review, we propose a systematic engineering framework with adaptive optimization and therapeutic enhancement for transforming S. Typhimurium into an effective anticancer LBP. This integrated strategy encompasses multiple facets, including strain attenuation, targeted enhancement, colonization optimization, therapeutic production, lysis-controlled release, and auxiliary modules. This review summarizes the key methodologies for engineering S. Typhimurium, highlighting its evolution from a pathogen to an antitumor vehicle. Furthermore, we summarize the multimodule collaborative engineering design and applications and call for more combinatorial strategies to enhance therapeutic efficacy. We also discuss the challenges and bottlenecks of engineered S. Typhimurium from the perspectives of genetic stability and clinical translation. Finally, we highlight how these synthetic biology advances are refining the mechanistic understanding of bacteria-mediated tumor therapy and paving the way toward safer, more effective, and clinically controllable anticancer strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Synthetic Biology and Biomanufacturing, Key Laboratory of Systems Bioengineering (Ministry of Education), State Key Laboratory of Synthetic Biology, Tianjin University, Tianjin 300072, China.
- Zhejiang Institute of Tianjin University (Shaoxing), Shaoxing 312300, China.
ORCID-Profile: Jianjun Qiao
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Liu, X., Zhang, P., Chen, D., Xu, S., Wu, S., & Qiao, J. (2026). Multiplexed Engineering of Salmonella Typhimurium for Targeted Cancer Therapies. ACS Synthetic Biology. https://doi.org/10.1021/acssynbio.6c00119
Vancouver
Liu X, Zhang P, Chen D, Xu S, Wu S, Qiao J. Multiplexed Engineering of Salmonella Typhimurium for Targeted Cancer Therapies. ACS Synthetic Biology. 2026. doi:10.1021/acssynbio.6c00119
BibTeX
@article{Liu2026,
author = {Liu, Xiaoli and Zhang, Peng and Chen, Danlei and Xu, Songlin and Wu, Shengbo and Qiao, Jianjun},
title = {Multiplexed Engineering of Salmonella Typhimurium for Targeted Cancer Therapies},
journal = {ACS Synthetic Biology},
year = {2026},
doi = {10.1021/acssynbio.6c00119}
}
EUVIMED